|Healthcare Review: EntreMed, Sequenom, Cytori Therapeutics, BioDelivery Sciences, Zogenix Are Notable Movers|
|By Staff and Wire Reports|
|Monday, 26 November 2012 15:28|
EntreMed, Inc. (NASDAQ:ENMD) is the biggest gainer and soared 18% after reporting positive results from preclinical breast cancer studies of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. Results indicated that the drug exhibited robust anticancer activity against a particularly difficult to treat subtype called "triple-negative" breast cancer. The data provides the basis for a predictive biomarker strategy to explore in future clinical trials.
Sequenom, Inc. (NASDAQ:SQNM) rose 6.11% to $4.52 after Stephens upgraded the stock to Overweight based on the American College of Obstetricians and Gynecologists Committee on Genetics recommendation that cell-free fetal DNA testing be used in high-risk women. The firm also doubles its price target to $8 from $4.
Cytori Therapeutics Inc. (USA)(NASDAQ:CYTX) shares added 10.26% to $3.78, off session high of $3.96. More than 677K shares have traded hands, compared to its average volume of 303k shares. Cytori Therapeutics, Inc. develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company’s technology is the Celuion family of products, which processes patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares slid 8.40% to $4.37 without any major news. BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs.
Zogenix, Inc. (NASDAQ:ZGNX) moves up 5% after saying it's appointed R. Scott Shively as its new chief commercial officer. Mr. Shively will be responsible for all of the company's commercial strategies and operations including the marketing for ZGNX's Sumavel DosePro, as well as the anticipated launch of ZohydroTM ER, which is pending FDA approval.